3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NETWORK
4
NIH
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
71
Lymphoma, Large B-Cell, Diffuse
51
Neoplasms
41
Lymphoma, Non-Hodgkin
41
Multiple Myeloma
40
Lymphoma
37
Recurrence
35
Lymphoma, Follicular
30
Carcinoma, Non-Small-Cell Lung
30
Leukemia, Lymphocytic, Chronic, B-Cell
29
Lymphoma, B-Cell
26
Triple Negative Breast Neoplasms
23
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Ovarian Neoplasms
17
Lymphoma, Mantle-Cell
17
Pancreatic Neoplasms
15
Neoplasm Metastasis
15
Leukemia
15
Squamous Cell Carcinoma of Head and Neck
12
Melanoma
12
Stomach Neoplasms
11
Colorectal Neoplasms
11
Lymphoma, B-Cell, Marginal Zone
10
Prostatic Neoplasms
9
Head and Neck Neoplasms
9
Lymphoma, T-Cell, Peripheral
8
Liposarcoma, Myxoid
8
Carcinoma, Renal Cell
8
Sarcoma
7
Interventions
fludarabine
1
Influenza Vaccines
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ganglioneuroblastoma
×
Cyclophosphamide
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled